Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma

T. Fukushima, Y. Miyazaki, S. Honda, F. Kawano, Y. Moriuchi, M. Masuda, Ryuji Tanosaki, A. Utsunomiya, N. Uike, S. Yoshida, J. Okamura, M. Tomonaga

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.

Original languageEnglish
Pages (from-to)829-834
Number of pages6
JournalLeukemia
Volume19
Issue number5
DOIs
Publication statusPublished - 2005 May
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Hematopoietic Stem Cell Transplantation
Survival
Graft vs Host Disease
Recurrence
Transplants
Immunosuppressive Agents
Secondary Prevention
Disease-Free Survival
Lymphoma
Japan
Multivariate Analysis
T-Lymphocytes
Drug Therapy

Keywords

  • Allogeneic HSCT
  • ATLL
  • GvATLL

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Fukushima, T., Miyazaki, Y., Honda, S., Kawano, F., Moriuchi, Y., Masuda, M., ... Tomonaga, M. (2005). Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia, 19(5), 829-834. https://doi.org/10.1038/sj.leu.2403682

Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. / Fukushima, T.; Miyazaki, Y.; Honda, S.; Kawano, F.; Moriuchi, Y.; Masuda, M.; Tanosaki, Ryuji; Utsunomiya, A.; Uike, N.; Yoshida, S.; Okamura, J.; Tomonaga, M.

In: Leukemia, Vol. 19, No. 5, 05.2005, p. 829-834.

Research output: Contribution to journalArticle

Fukushima, T, Miyazaki, Y, Honda, S, Kawano, F, Moriuchi, Y, Masuda, M, Tanosaki, R, Utsunomiya, A, Uike, N, Yoshida, S, Okamura, J & Tomonaga, M 2005, 'Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma', Leukemia, vol. 19, no. 5, pp. 829-834. https://doi.org/10.1038/sj.leu.2403682
Fukushima, T. ; Miyazaki, Y. ; Honda, S. ; Kawano, F. ; Moriuchi, Y. ; Masuda, M. ; Tanosaki, Ryuji ; Utsunomiya, A. ; Uike, N. ; Yoshida, S. ; Okamura, J. ; Tomonaga, M. / Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. In: Leukemia. 2005 ; Vol. 19, No. 5. pp. 829-834.
@article{ff72ed27ecb149038a777193d5317610,
title = "Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma",
abstract = "Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3{\%}, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.",
keywords = "Allogeneic HSCT, ATLL, GvATLL",
author = "T. Fukushima and Y. Miyazaki and S. Honda and F. Kawano and Y. Moriuchi and M. Masuda and Ryuji Tanosaki and A. Utsunomiya and N. Uike and S. Yoshida and J. Okamura and M. Tomonaga",
year = "2005",
month = "5",
doi = "10.1038/sj.leu.2403682",
language = "English",
volume = "19",
pages = "829--834",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma

AU - Fukushima, T.

AU - Miyazaki, Y.

AU - Honda, S.

AU - Kawano, F.

AU - Moriuchi, Y.

AU - Masuda, M.

AU - Tanosaki, Ryuji

AU - Utsunomiya, A.

AU - Uike, N.

AU - Yoshida, S.

AU - Okamura, J.

AU - Tomonaga, M.

PY - 2005/5

Y1 - 2005/5

N2 - Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.

AB - Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy. Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL. To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002. All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients. The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively. Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect. However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse. These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD. A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.

KW - Allogeneic HSCT

KW - ATLL

KW - GvATLL

UR - http://www.scopus.com/inward/record.url?scp=20844438354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844438354&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403682

DO - 10.1038/sj.leu.2403682

M3 - Article

C2 - 15744352

AN - SCOPUS:20844438354

VL - 19

SP - 829

EP - 834

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -